Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $11.90, for a total transaction of $23,800.00. Following the sale, the president now directly owns 2,877,138 shares in the company, valued at $34,237,942.20. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.

Gyre Therapeutics Stock Performance

Shares of NASDAQ GYRE opened at $11.62 on Thursday. The company’s 50 day simple moving average is $11.17 and its 200 day simple moving average is $12.35. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

Several large investors have recently bought and sold shares of GYRE. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the period. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics in the third quarter worth $334,000. FMR LLC acquired a new stake in Gyre Therapeutics in the third quarter worth $47,000. State Street Corp raised its holdings in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the period. Finally, Barclays PLC raised its holdings in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. 23.99% of the stock is currently owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.